Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market is suffering.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Growth-seeking investors have had a terrible time watching their investments decline on the stock market. Those bullish on long-term prospects for their investments might stick around and hope for the best. Others have cut their losses to invest their money elsewhere. Unfortunately for investors who have faith in cannabis stocks, the situation does not appear to be getting better soon.

The announcement of cannabis legalization for recreational use was a massive game changer for Canadian cannabis producers like Aurora Cannabis (TSX:ACB)(NASDAQ:ACB). The entire cannabis industry has been struck with significant losses in recent weeks. However, Aurora Cannabis leads the downward charge, hitting new all-time lows for the first time since it went public.

What is happening?

Investor sentiment has a massive role to play in the price movements for publicly traded companies on stock markets, and Aurora Cannabis has not given its investors many reasons to be very happy with its performance. The company recently reported a new record of losses in its quarterly earnings.

Aurora Cannabis also sold off facilities crucial to its operations as a cost-cutting measure, making things even worse for the beleaguered cannabis giant. Aurora Cannabis recently agreed to purchase 61.2 million units on a bought deal basis for gross proceeds amounting to US$150 million.

It is a type of financing that makes the investment bank liable to purchase the entire stock offer of the issuing company. The capital-raising tactic is a sound move financially for the company, because it eliminates the risk for Aurora Cannabis. Unfortunately, the move also puts its shareholders at significant risk of dilution.

Aurora Cannabis had 168 million total outstanding shares by the end of 2020. As of March 2022, that number has spiked to 215 million, making its shares worth far less for existing investors. The company’s revenues have been declining for several years, but its outstanding shares keep increasing.

The decision to resort to dilution to finance its operations comes as no surprise after posting a $1 billion loss in its recent quarter. Last year, the same quarter saw a net loss of just $160 million for the company.

Where is the cannabis industry going?

The financial struggles are not limited to Aurora Cannabis alone. The entire cannabis sector has faced issues due to a saturated market exhibiting slow growth. The black market makes matters worse by eating into their top lines. Many consumers still prefer buying from unregulated sources because of more affordable prices.

The industry-specific obstacles have combined with weakness in broader equity markets to weigh heavily on cannabis stocks. Growth stocks are not performing well, and interest rate hikes will make matters worse.

Foolish takeaway

Using cost-cutting measures to improve its chances of turning a profit soon has made Aurora Cannabis a risky bet for its investors. The cannabis industry might see some improvements in the long run as better regulations come into place.

Unfortunately, it could still take several years for Aurora Cannabis and its peers to become profitable. It might be best to avoid allocating capital to buying Aurora Cannabis shares for a long time.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »